SCM
PTX

Stonepine Capital Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Stonepine Capital Management’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-321,586
Closed -$3.38M – 27
2016
Q1 		$3.38M Buy
321,586
+73,121
+29% +$1.45M 3.98% 8
2015
Q4 		$7.33M Buy
+248,465
New +$7.51M 8.59% 6

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Stonepine Capital Management's PTX Position: Q2 2016 in Review

Stonepine Capital Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2016, closing a stake of 321,586 shares — an estimated $3.38M sold.

Stonepine Capital Management first reported a position in PTX in Q4 2015 and held it in 2 quarters. The position peaked at $7.33M in Q4 2015. 56 funds tracked by Wall St. Rank hold PTX as of Q2 2016.

  • Stonepine Capital Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2016 after selling out during the quarter.
  • Stonepine Capital Management sold 321,586 Pernix Therapeutics Holdings, Inc. shares in Q2 2016, an estimated $3.38M.
  • Stonepine Capital Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q4 2015 and held it in 2 quarters.
  • Stonepine Capital Management's Pernix Therapeutics Holdings, Inc. position peaked at $7.33M in Q4 2015.
  • 56 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2016.

Based on Stonepine Capital Management's 13F filing for Q2 2016, filed 10 Aug 2016.